Veru Inc (VERU) - Net Assets
Based on the latest financial reports, Veru Inc (VERU) has net assets worth $37.12 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($47.57 Million) and total liabilities ($10.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VERU asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $37.12 Million |
| % of Total Assets | 78.05% |
| Annual Growth Rate | 3.15% |
| 5-Year Change | -87.96% |
| 10-Year Change | -45.97% |
| Growth Volatility | 206.74 |
Veru Inc - Net Assets Trend (1990–2025)
This chart illustrates how Veru Inc's net assets have evolved over time, based on quarterly financial data. Also explore Veru Inc (VERU) total assets for the complete picture of this company's asset base.
Annual Net Assets for Veru Inc (1990–2025)
The table below shows the annual net assets of Veru Inc from 1990 to 2025. For live valuation and market cap data, see Veru Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $18.33 Million | -43.27% |
| 2024-09-30 | $32.32 Million | +64.23% |
| 2023-09-30 | $19.68 Million | -76.23% |
| 2022-09-30 | $82.80 Million | -45.63% |
| 2021-09-30 | $152.29 Million | +405.77% |
| 2020-09-30 | $30.11 Million | -6.87% |
| 2019-09-30 | $32.33 Million | +9.67% |
| 2018-09-30 | $29.48 Million | -39.15% |
| 2017-09-30 | $48.45 Million | +42.79% |
| 2016-09-30 | $33.93 Million | +2.42% |
| 2015-09-30 | $33.13 Million | +18.06% |
| 2014-09-30 | $28.07 Million | -10.63% |
| 2013-09-30 | $31.40 Million | +29.67% |
| 2012-09-30 | $24.22 Million | +44.56% |
| 2011-09-30 | $16.75 Million | +3.85% |
| 2010-09-30 | $16.13 Million | +24.53% |
| 2009-09-30 | $12.95 Million | +33.42% |
| 2008-09-30 | $9.71 Million | +30.37% |
| 2007-09-30 | $7.45 Million | +56.06% |
| 2006-09-30 | $4.77 Million | +44.19% |
| 2005-09-30 | $3.31 Million | +81.32% |
| 2004-09-30 | $1.83 Million | +270.16% |
| 2003-09-30 | $493.13K | -21.76% |
| 2002-09-30 | $630.28K | +1104.60% |
| 2001-09-30 | $52.32K | +107.55% |
| 2000-09-30 | $-693.07K | -140.23% |
| 1999-09-30 | $1.72 Million | -41.29% |
| 1998-09-30 | $2.93 Million | -17.44% |
| 1997-09-30 | $3.55 Million | -52.93% |
| 1996-09-30 | $7.55 Million | -0.64% |
| 1995-09-30 | $7.60 Million | -40.16% |
| 1994-09-30 | $12.70 Million | +195.35% |
| 1993-09-30 | $4.30 Million | -21.82% |
| 1992-09-30 | $5.50 Million | +17.02% |
| 1991-09-30 | $4.70 Million | -24.19% |
| 1990-09-30 | $6.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Veru Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31629591400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $148.69K | 0.81% |
| Other Components | $335.48 Million | 1829.96% |
| Total Equity | $18.33 Million | 100.00% |
Veru Inc Competitors by Market Cap
The table below lists competitors of Veru Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MUI Properties Bhd
KLSE:3913
|
$36.27 Million |
|
Oncopeptides AB
ST:ONCO
|
$36.29 Million |
|
Biohit Oyj B
HE:BIOBV
|
$36.29 Million |
|
Milux Corporation Bhd
KLSE:7935
|
$36.29 Million |
|
Hipay Group SA
PA:ALHYP
|
$36.24 Million |
|
OTRS AG
F:TR9
|
$36.22 Million |
|
Elliptic Laboratories AS
OL:ELABS
|
$36.20 Million |
|
Sol Strategies Inc. Common Shares
NASDAQ:STKE
|
$36.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Veru Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,316,712 to 18,332,670, a change of -13,984,042 (-43.3%).
- Net loss of 22,726,279 reduced equity.
- Other comprehensive income increased equity by 581,519.
- Other factors increased equity by 8,160,718.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-22.73 Million | -123.97% |
| Other Comprehensive Income | $581.52K | +3.17% |
| Other Changes | $8.16 Million | +44.51% |
| Total Change | $- | -43.27% |
Book Value vs Market Value Analysis
This analysis compares Veru Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.19x to 1.81x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-09-30 | $1.89 | $2.26 | x |
| 1991-09-30 | $1.41 | $2.26 | x |
| 1992-09-30 | $1.59 | $2.26 | x |
| 1993-09-30 | $1.12 | $2.26 | x |
| 1994-09-30 | $2.62 | $2.26 | x |
| 1995-09-30 | $1.27 | $2.26 | x |
| 1996-09-30 | $1.14 | $2.26 | x |
| 1997-09-30 | $0.42 | $2.26 | x |
| 1998-09-30 | $0.29 | $2.26 | x |
| 1999-09-30 | $0.16 | $2.26 | x |
| 2000-09-30 | $-0.05 | $2.26 | x |
| 2001-09-30 | $0.00 | $2.26 | x |
| 2002-09-30 | $0.04 | $2.26 | x |
| 2003-09-30 | $0.03 | $2.26 | x |
| 2004-09-30 | $0.09 | $2.26 | x |
| 2005-09-30 | $1.43 | $2.26 | x |
| 2006-09-30 | $1.80 | $2.26 | x |
| 2007-09-30 | $2.82 | $2.26 | x |
| 2008-09-30 | $3.47 | $2.26 | x |
| 2009-09-30 | $4.66 | $2.26 | x |
| 2010-09-30 | $0.57 | $2.26 | x |
| 2011-09-30 | $5.78 | $2.26 | x |
| 2012-09-30 | $8.37 | $2.26 | x |
| 2013-09-30 | $1.09 | $2.26 | x |
| 2014-09-30 | $9.72 | $2.26 | x |
| 2015-09-30 | $11.46 | $2.26 | x |
| 2016-09-30 | $11.73 | $2.26 | x |
| 2017-09-30 | $13.99 | $2.26 | x |
| 2018-09-30 | $5.47 | $2.26 | x |
| 2019-09-30 | $5.11 | $2.26 | x |
| 2020-09-30 | $4.51 | $2.26 | x |
| 2021-09-30 | $18.17 | $2.26 | x |
| 2022-09-30 | $10.33 | $2.26 | x |
| 2023-09-30 | $2.32 | $2.26 | x |
| 2024-09-30 | $2.40 | $2.26 | x |
| 2025-09-30 | $1.25 | $2.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Veru Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -123.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.63x
- Recent ROE (-123.97%) is above the historical average (-139.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | 4.84% | 2.80% | 1.16x | 1.48x | $-320.00K |
| 1991 | -31.91% | -11.45% | 1.60x | 1.74x | $-1.97 Million |
| 1992 | -78.18% | -38.39% | 1.11x | 1.84x | $-4.85 Million |
| 1993 | -86.05% | -29.60% | 1.24x | 2.35x | $-4.13 Million |
| 1994 | -23.62% | -18.52% | 0.87x | 1.46x | $-4.27 Million |
| 1995 | -109.21% | -377.27% | 0.16x | 1.82x | $-9.06 Million |
| 1996 | -114.69% | -419.54% | 0.15x | 1.82x | $-9.42 Million |
| 1997 | -157.80% | -192.33% | 0.35x | 2.35x | $-5.96 Million |
| 1998 | -114.41% | -61.59% | 0.72x | 2.58x | $-3.65 Million |
| 1999 | -217.67% | -79.53% | 0.72x | 3.78x | $-3.92 Million |
| 2000 | 0.00% | -63.99% | 1.40x | 0.00x | $-3.62 Million |
| 2001 | -2238.51% | -17.44% | 1.55x | 82.77x | $-1.18 Million |
| 2002 | -552.32% | -41.36% | 1.51x | 8.83x | $-3.54 Million |
| 2003 | -480.64% | -26.20% | 1.80x | 10.21x | $-2.42 Million |
| 2004 | -110.60% | -22.87% | 1.96x | 2.46x | $-2.20 Million |
| 2005 | -40.96% | -12.15% | 1.97x | 1.72x | $-1.69 Million |
| 2006 | 5.91% | 1.90% | 1.99x | 1.56x | $-195.21K |
| 2007 | 22.74% | 8.77% | 1.73x | 1.50x | $949.17K |
| 2008 | 51.16% | 19.38% | 1.85x | 1.42x | $4.00 Million |
| 2009 | 50.45% | 23.73% | 1.49x | 1.43x | $5.24 Million |
| 2010 | 41.76% | 30.32% | 1.21x | 1.14x | $5.12 Million |
| 2011 | 32.23% | 29.08% | 0.95x | 1.16x | $3.72 Million |
| 2012 | 63.17% | 43.67% | 1.15x | 1.26x | $12.88 Million |
| 2013 | 45.67% | 45.59% | 0.89x | 1.12x | $11.20 Million |
| 2014 | 8.67% | 9.93% | 0.77x | 1.13x | $-373.47K |
| 2015 | 13.12% | 13.33% | 0.87x | 1.13x | $1.03 Million |
| 2016 | 1.02% | 1.56% | 0.57x | 1.14x | $-3.05 Million |
| 2017 | -13.65% | -48.42% | 0.25x | 1.14x | $-11.46 Million |
| 2018 | -81.20% | -150.89% | 0.33x | 1.64x | $-26.89 Million |
| 2019 | -37.17% | -37.79% | 0.59x | 1.66x | $-15.25 Million |
| 2020 | -63.01% | -44.55% | 0.83x | 1.71x | $-21.98 Million |
| 2021 | 4.86% | 12.07% | 0.34x | 1.17x | $-7.84 Million |
| 2022 | -101.18% | -212.88% | 0.29x | 1.63x | $-92.06 Million |
| 2023 | -473.38% | -571.60% | 0.33x | 2.54x | $-95.12 Million |
| 2024 | -116.97% | -223.86% | 0.28x | 1.87x | $-41.03 Million |
| 2025 | -123.97% | 0.00% | 0.00x | 1.63x | $-24.56 Million |
Industry Comparison
This section compares Veru Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Veru Inc (VERU) | $37.12 Million | 4.84% | 0.28x | $36.27 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more